If you’re looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here’s why these blue chip ASX 200 shares are highly rated right now:
CSL Limited (ASX: CSL)
The first ASX 200 blue chip share that could be in the buy zone is CSL. It is the biotherapeutics giant behind the CSL Behring business, which has developed a range of lifesaving and lucrative plasma therapies. In addition, the company has a growing Seqirus vaccine business and is on the brink of acquiring Vifor Pharma, which is focused on iron deficiency, nephrology and cardio-renal therapies.
The team at Morgans is positive on the company, particularly given the recovery in plasma collections. It recently put an add rating and $327.60 price target on its shares. Morgans commented:
“Promisingly, plasma collections continue to improve, although remain slightly below pre-pandemic levels, and while industry wide issues remain (eg Omicron; staffing; increase costs), the worst appears behind us.”
“While near term challenges remain, the ongoing recovery in plasma collections, coupled with management’s confidence, paints a favourable earnings picture.”
Goodman Group (ASX: GMG)
Another ASX 200 blue chip share to consider is Goodman. It is an integrated property company with operations throughout Australia, New Zealand, Asia, Europe, the United Kingdom, North America and Brazil.
The company notes that its global property expertise, integrated own+develop+manage customer service offering and significant investment management platform ensures that it creates innovative property solutions that meet the individual requirements of its customers, such as Amazon, while seeking to deliver long-term returns for investors.
Citi is very positive on Goodman and currently has a buy rating and $29.50 price target on its shares. Its analysts believe Goodman could outperform its upgraded guidance in FY 2022. It commented:
“GMG’s 1H22 EPS of 41.9c was 12% ahead of Visible Alpha consensus (37.3c) and 6% ahead of Citi (39.5c). FY22 EPS guidance was upgraded for the 2nd time in 6 months to 20% growth, or EPS of 78.7c, +1.5% ahead of ingoing consensus of 77.5c. FY22 DPS guidance was retained at 30c.”
“We continue to see guidance as conservative, with our EPS estimates rising 5% in FY22 and c. 6% thereafter. We now forecast c. 23% EPS growth in FY22 and c. 19% EPS CAGR from FY21-FY24. Our TP increases 5% on higher asset values and higher earnings. GMG remains OUR top pick in the sector.”
The post 2 blue chip ASX 200 shares analysts are urging investors to buy appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- Do CSL shares deserve a spot in the ASX ‘hall of fame’?
- Brickworks (ASX:BKW) share price on watch amid 269% first half profit jump
- Top brokers name 3 ASX shares to buy today
- The next ASX share ready to join the 20-bagger club: expert
- Which ASX 200 shares is AFIC (ASX:AFI) betting on to make money?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/jIl6rpf
Leave a Reply